Aeolus Strengthens Board of Directors
Monday, May 20, 2013
Aeolus Pharmaceuticals, Inc. announced the appointment of John M. Clerici, Mitchell D. Kaye, and Jeffrey A. Scott, M.D., to its board of directors.
Immunotec Announces New CEO
Monday, May 20, 2013
Immunotec Inc. announced the appointment of Mr. Charles L. Orr as its Chief Executive Officer.
New £23m Research Unit will use Advances in Genetics to Help Reduce Risk of Disease
Monday, May 20, 2013
Unit will exploit the latest advances in genetics to improve understanding of how changes to lifestyle or environment can reduce the risk of disease.
GFT505 Reduces the Risk of Cardiovascular Events
Friday, May 17, 2013
Treatment with GFT505 significantly reduces the level of “remnant cholesterol”.
Curie-Cancer and Roche Strengthen Partnership
Friday, May 17, 2013
Curie-Cancer and Roche build on four years partnership by increasing translational research programs, speeding up development of new cancer treatments.
Nuvo Research Announces Scientific Presentation at the Annual Meeting of AAI
Friday, May 17, 2013
Data evaluating WF10's therapeutic impact on signs and symptoms of experimentally induced rheumatoid arthritis in mice.
Merck KGaA and Quintiles Announce Innovative Clinical Development Partnership
Friday, May 17, 2013
Agreement creates unique strategic collaboration for development and clinical trial execution.
Algeta: FDA Approves Xofigo (radium-223 dichloride)
Friday, May 17, 2013
Xofigo shown in a pivotal phase III trial to significantly improve overall survival.
AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease
Friday, May 17, 2013
First selective JAK1 inhibitor to enter Phase 2 studies in Crohn's disease.
|
|
|
|
|
|
